Literature DB >> 4007028

Decreased renal clearance of digoxin in chronic congestive heart failure.

M A Naafs, C van der Hoek, S van Duin, G Koorevaar, W Schopman, J Silberbusch.   

Abstract

Renal digoxin clearance was compared in patients suffering from atrial fibrillation with well preserved cardiac function (n = 9; salt intake +/- 170 mmol daily) and patients with chronic congestive heart failure (n = 10; salt intake 50 mmol daily and maintenance treatment with diuretics). There was no difference between the groups concerning digoxin dosage, creatinine clearance, diuresis or sodium excretion in the urine. Digoxin clearance in chronic heart failure proved to be significantly lower than in atrial fibrillation (48 +/- 21 vs 71 +/- 36 ml X min-1, p less than 0.05), and Cdig/Ccreat was similarly reduced at 0.73 +/- 0.15 compared to 1.09 +/- 0.27 (p less than 0.005). Steady state serum digoxin concentration was significantly higher in patients with congestive heart failure (1.44 +/- 0.47 vs 0.87 +/- 0.33 micrograms X 1(-1), p less than 0.01). Chronic congestive heart failure is a state with reduced digoxin clearance by the kidney, which could lead to digoxin intoxication not explicable by overdose, reduced renal function or the effect of interacting drugs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007028     DOI: 10.1007/bf00543318

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Determinants of the renal clearance of digoxin.

Authors:  H Halkin; L B Sheiner; C C Peck; K L Melmon
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Serum levels and renal excretion of digoxin in the elderly. A comparison between three different preparations.

Authors:  E Iisalo; I Ruikka
Journal:  Acta Med Scand       Date:  1974 Jul-Aug

3.  Renal tubular secretion of digoxin.

Authors:  E Steiness
Journal:  Circulation       Date:  1974-07       Impact factor: 29.690

4.  Endogenous digitalis-like substance in plasma of volume-expanded dogs.

Authors:  K A Gruber; J M Whitaker; V M Buckalew
Journal:  Nature       Date:  1980-10-23       Impact factor: 49.962

5.  Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin.

Authors:  T P Gibson; A P Quintanilla
Journal:  J Pharmacol Exp Ther       Date:  1981-10       Impact factor: 4.030

6.  Suppression of renal excretion of digoxin in hypokalemic patients.

Authors:  E Steiness
Journal:  Clin Pharmacol Ther       Date:  1978-05       Impact factor: 6.875

7.  Effects of quinidine on serum digoxin concentration: a prospective study.

Authors:  D R Mungall; R P Robichaux; W Perry; J W Scott; A Robinson; T Burelle; D Hurst
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

8.  Inhibition of digoxin absorption by neomycin.

Authors:  J Lindenbaum; R M Maulitz; V P Butler
Journal:  Gastroenterology       Date:  1976-09       Impact factor: 22.682

9.  An endogenous digoxin-like substance in patients with renal impairment.

Authors:  S W Graves; B Brown; R Valdes
Journal:  Ann Intern Med       Date:  1983-11       Impact factor: 25.391

10.  Spironolactone-induced changes in digoxin kinetics.

Authors:  S Waldorff; J D Andersen; N Heebøll-Nielsen; O G Nielsen; E Moltke; U Sørensen; E Steiness
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

View more
  9 in total

Review 1.  The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence.

Authors:  Arduino A Mangoni; Elzbieta A Jarmuzewska
Journal:  Br J Clin Pharmacol       Date:  2018-10-14       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics in heart failure. An updated review.

Authors:  F V Shammas; K Dickstein
Journal:  Clin Pharmacokinet       Date:  1988-08       Impact factor: 6.447

4.  Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.

Authors:  E Yukawa; F Suematu; M Yukawa; M Minemoto; S Ohdo; S Higuchi; Y Goto; T Aoyama
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

Review 6.  A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.

Authors:  Mariam H Abdel Jalil; Noura Abdullah; Mervat M Alsous; Mohammad Saleh; Khawla Abu-Hammour
Journal:  Br J Clin Pharmacol       Date:  2020-04-01       Impact factor: 4.335

7.  Some pharmacokinetic and pharmacodynamic interactions between digoxin and gentamicin.

Authors:  D Staneva-Stoytcheva; E Kristeva; K Prodanova
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

8.  Decreased vancomycin clearance in patients with congestive heart failure.

Authors:  Yuko Shimamoto; Tsuyoshi Fukuda; Shinjiro Tominari; Kyoko Fukumoto; Kazuyuki Ueno; Min Dong; Kazuhiko Tanaka; Takuma Shirasaka; Katsuya Komori
Journal:  Eur J Clin Pharmacol       Date:  2012-07-12       Impact factor: 2.953

9.  Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data.

Authors:  Toshinori Hirai; Hidefumi Kasai; Miyoko Naganuma; Nobuhisa Hagiwara; Tsuyoshi Shiga
Journal:  BMC Pharmacol Toxicol       Date:  2022-02-10       Impact factor: 2.483

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.